-
Loading metrics
Glecaprevir–pibrentasvir for chronic hepatitis C: Comparing treatment effect in patients with and without end-stage renal disease in a real-world setting
-
Hsu-Heng Yen ,
Contributed equally to this work with: Hsu-Heng Yen, Kun-Ching Chou
Roles Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Writing – original draft, Writing – review & editing
* E-mail: 91646@cch.org.tw, blaneyen@gmail.com (HHY); 84798@cch.org.tw (KCC)
Affiliations Division of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan, Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, General Education Center, Chienkuo Technology University, Changhua, Taiwan
⨯ - Pei-Yuan Su,
- Ya-Huei Zeng,
- I-Ling Liu,
- Siou-Ping Huang,
- Yu-Chun Hsu,
- Yang-Yuan Chen,
- Chia-Wei Yang,
- Shun-Sheng Wu,
- Kun-Ching Chou
http://orcid.org/0000-0002-3494-2245
Glecaprevir–pibrentasvir for chronic hepatitis C: Comparing treatment effect in patients with and without end-stage renal disease in a real-world setting
- Hsu-Heng Yen,
- Pei-Yuan Su,
- Ya-Huei Zeng,
- I-Ling Liu,
- Siou-Ping Huang,
- Yu-Chun Hsu,
- Yang-Yuan Chen,
- Chia-Wei Yang,
- Shun-Sheng Wu,
- Kun-Ching Chou
x
- Published: August 13, 2020
- https://doi.org/10.1371/journal.pone.0237582